These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 25580750)
1. Pediatric dyslipidemia: recommendations for clinical management. Wilson DP; McNeal C; Blackett P South Med J; 2015 Jan; 108(1):7-14. PubMed ID: 25580750 [TBL] [Abstract][Full Text] [Related]
2. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol]. Brea Hernando ÁJ Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539 [TBL] [Abstract][Full Text] [Related]
3. [Multimodal therapy of dyslipidemia]. Stahn A; Hanefeld M Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173 [TBL] [Abstract][Full Text] [Related]
4. The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines? Flink L; Underberg JA; Newman JD; Gianos E Curr Atheroscler Rep; 2015 Apr; 17(4):494. PubMed ID: 25690588 [TBL] [Abstract][Full Text] [Related]
5. [Lipid management--treatment goal and strategy]. Koshiyama H Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303 [TBL] [Abstract][Full Text] [Related]
6. Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia: Evidence Report and Systematic Review for the US Preventive Services Task Force. Lozano P; Henrikson NB; Morrison CC; Dunn J; Nguyen M; Blasi PR; Whitlock EP JAMA; 2016 Aug; 316(6):634-44. PubMed ID: 27532918 [TBL] [Abstract][Full Text] [Related]
7. Lipids and Cerebrovascular Disease: Research and Practice. Yaghi S; Elkind MS Stroke; 2015 Nov; 46(11):3322-8. PubMed ID: 26451029 [No Abstract] [Full Text] [Related]
8. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Jacobson TA Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969 [TBL] [Abstract][Full Text] [Related]
15. Recognition and management of dyslipidemia in children and adolescents. Kwiterovich PO J Clin Endocrinol Metab; 2008 Nov; 93(11):4200-9. PubMed ID: 18697860 [TBL] [Abstract][Full Text] [Related]
16. The use of lipid-lowering drug therapy in children and adolescents. Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879 [TBL] [Abstract][Full Text] [Related]
17. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention]. Olsson AG Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387 [No Abstract] [Full Text] [Related]
18. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism. Delluc A; Malécot JM; Kerspern H; Nowak E; Carre JL; Mottier D; Le Gal G; Lacut K Atherosclerosis; 2012 Jan; 220(1):184-8. PubMed ID: 22035572 [TBL] [Abstract][Full Text] [Related]
19. Universal screening and drug treatment of dyslipidemia in children and adolescents. Psaty BM; Rivara FP JAMA; 2012 Jan; 307(3):257-8. PubMed ID: 22174386 [No Abstract] [Full Text] [Related]
20. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ; Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]